50-12-106. Effect on insurance coverage and health care services. (1) This part does not:
(a) expand the coverage required of an insurer under Title 33 or of the state or a local government under Title 2 or Title 53;
(b) affect the requirements for insurance coverage of routine patient costs for patients involved in approved cancer clinical trials pursuant to 2-18-704, 33-22-101, 33-22-153, 33-31-111, 33-35-306, 53-4-1005, or 53-6-101;
(c) require a health plan, third-party administrator, or governmental agency to pay costs associated with the use, care, or treatment of an eligible patient with an investigational drug, biological product, or device; or
(d) require a health care facility to provide new or additional services.
(2) A health plan, third-party administrator, or governmental agency may provide coverage for the cost of an investigational drug, biological product, or device or the cost of services related to the use of an investigational drug, biological product, or device under this part.
(3) A health care facility may approve the use of an investigational drug, biological product, or device in the health care facility.
History: En. Sec. 6, Ch. 135, L. 2015.